Better Therapeutics, Inc.
BTTX
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.10M | 21.11M | 21.69M | 21.82M | 22.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.61M | 35.27M | 37.84M | 38.26M | 42.04M |
| Operating Income | -29.61M | -35.27M | -37.84M | -38.26M | -42.04M |
| Income Before Tax | -31.56M | -37.11M | -39.45M | -39.75M | -44.89M |
| Income Tax Expenses | 9.00K | 9.00K | 8.00K | 7.00K | 0.00 |
| Earnings from Continuing Operations | -31.57 | -37.12 | -39.46 | -39.76 | -44.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.57M | -37.12M | -39.46M | -39.76M | -44.89M |
| EBIT | -29.61M | -35.27M | -37.84M | -38.26M | -42.04M |
| EBITDA | -27.21M | -33.01M | -35.73M | -36.24M | -40.01M |
| EPS Basic | -1.16 | -1.49 | -1.66 | -1.68 | -1.96 |
| Normalized Basic EPS | -0.72 | -0.93 | -1.04 | -1.05 | -1.26 |
| EPS Diluted | -1.16 | -1.49 | -1.66 | -1.68 | -1.96 |
| Normalized Diluted EPS | -0.72 | -0.93 | -1.04 | -1.05 | -1.26 |
| Average Basic Shares Outstanding | 117.28M | 102.48M | 94.86M | 94.45M | 90.39M |
| Average Diluted Shares Outstanding | 117.28M | 102.48M | 94.86M | 94.45M | 90.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |